Interim Report from a Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor: Clinical Activity and Favorable Safety in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Franck Morschhauser; Gilles Salles; Pamela McKay; Hervé Tilly; Anna Schmitt; John Gerecitano; Peter Johnson; Steven Le Gouill; Michael Dickinson; Christophe Fruchart; Thierry Lamy; Aristeidis Chaidos; Wojciech Jurczak; Stephen Opat; John Radford; Pier Luigi Zinzani; Sarit Assouline; Guillaume Cartron; Alicia Clawson; Natasha Picazio; Scott Ribich; Stephen Blakemore; John Larus; Harry Miao; Mark Woodruff; Peter Ho; Vincent Ribrag

doi:10.1016/j.clml.2017.07.227

$Interim Report from a Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor: Clinical Activity and Favorable Safety in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma$

Article de revue

Avec comité de lecture

Interim Report from a Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor: Clinical Activity and Favorable Safety in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Franck Morschhauser, Gilles Salles, Pamela McKay, Hervé Tilly, Anna Schmitt, John Gerecitano, Peter Johnson, Steven Le Gouill, Michael Dickinson, Christophe Fruchart, …

Clinical lymphoma, myeloma and leukemia, Vol.17, pp.S380-S381

09/2017

DOI: https://doi.org/10.1016/j.clml.2017.07.227

Indicateurs

1 Consultations de la notice

Détails

Titre: Interim Report from a Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor: Clinical Activity and Favorable Safety in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Créateurs - sans rôle: Franck Morschhauser - Centre Hospitalier Universitaire, Lille, France
Gilles Salles - Lyon-Sud Hospital Center, Pierre-Bénite, France
Pamela McKay - Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
Hervé Tilly - Centre de lutte Contre le Cancer Henri Becquerel, Rouen, France
Anna Schmitt - Institut Bergonié, Bordeaux, France
John Gerecitano - Memorial Sloan Kettering Cancer Center
Peter Johnson - Southampton General Hospital, Southampton, United Kingdom
Steven Le Gouill - Universite De Nantes, Nantes, France
Michael Dickinson - Peter MacCallum Cancer Centre
Christophe Fruchart - Centre François Baclesse, Caen, France
Thierry Lamy - Centre Hospitalier Universitaire de Rennes
Aristeidis Chaidos - Hammersmith Hospital, Shepherd's Bush, United Kingdom
Wojciech Jurczak - UJCM, Krakow, Poland
Stephen Opat - Monash University, Clayton, Australia
John Radford - University of Manchester
Pier Luigi Zinzani - University of Bologna, Bologna, Italy
Sarit Assouline - McGill University
Guillaume Cartron - CHU Montpellier, Montpellier, France
Alicia Clawson - Epizyme, Cambridge, United States
Natasha Picazio - Epizyme, Cambridge, United States
Scott Ribich - Epizyme, Cambridge, United States
Stephen Blakemore - Epizyme, Cambridge, United States
John Larus - Epizyme, Morrisville, United States
Harry Miao - Epizyme, Cambridge, United States
Mark Woodruff - Epizyme, Cambridge, United States
Peter Ho - Epizyme, Cambridge, United States
Vincent Ribrag - Gustave Roussy, Villejuif, France
Détails de publication: Clinical lymphoma, myeloma and leukemia, Vol.17, pp.S380-S381
Éditeur: Elsevier Inc
Identifiants: 99139797609311
Unité académique: Institut de Génétique Moléculaire de Montpellier - IGMM
Langue: English
Type de ressource: Journal article